An interventional study of Octreotide and Placebo in Esophageal Neoplasms, Stomach Neoplasms and Weight Loss, sponsored by St. James's Hospital, Ireland. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-27.
Sponsored by St. James's Hospital, Ireland · Not applicable, Interventional, and Basic science
Improvements to treatment strategies for patients with cancers of the upper gastrointestinal tract have produced a large population of people who remain free from cancer recurrence in the long term following treatment.
Surgery is the cornerstone of treatment for patients with these cancers, but while surgical removal of the tumour may offer the best chance of cure, these are major operations associated with specific long term complications. Weight loss and poor nutrition are common problems among patients who attain long-term cancer remission and cure after surgery. The mechanisms underlying these problems are not well understood and therefore treatment options are limited.
Our research has demonstrated increased levels of chemical messengers (gut hormones) released from the gastrointestinal tract after meals in patients who have previously undergone this type of surgery. These chemical messengers play a role in controlling appetite and interest in food, and increased levels after surgery may reduce interest in eating. Understanding the role of gut hormones in the control of appetite may allow us to use certain medications to block gut hormones and hence increase appetite, allowing patients to eat more and regain weight, preventing nutritional problems after surgery.
In this study, the investigators aim to determine whether exaggerated gut hormone secretion causes reduced appetite and interest in food after surgery. The information gained from this study may help us to develop treatments for patients with weight loss and nutritional problems after surgery.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 40 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →St. James's Hospital, Ireland is the lead sponsor of 28 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Double-blind single dose octreotide-placebo crossover
Drug: Octreotide · Drug: Placebo
Double-blind single dose octreotide-placebo crossover
Drug: Octreotide · Drug: Placebo
Double-blind single dose octreotide-placebo crossover
Drug: Octreotide · Drug: Placebo
Double-blind single dose octreotide-placebo crossover
Drug: Octreotide · Drug: Placebo
Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
Also known as: Sandostatin
Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
Progressive ratio task breakpoint for a sweet-fat reward
Time frame: 3 hours
Number of rewards consumed
Time frame: 3 hours
Subjective symptom score
Time frame: 3 hours
Sigstad score
Both categorical and continuous
Time frame: 3 hours
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. James's Hospital, Ireland